The Journal of Allergy and Clinical Immunology
Volume 120, Issue 5 , Pages 1036-1042 , November 2007

Determinants of response to fluticasone propionate and salmeterol/fluticasone propionate combination in the Gaining Optimal Asthma controL study

  • Søren E. Pedersen, MD, DMSc

      Affiliations

    • Department of Pediatrics, University of Southern Denmark, Pediatric Research Unit, Kolding Hospital, Kolding, Denmark
    • Corresponding Author InformationReprint requests: Søren E. Pedersen, MD, DMSc, University of Southern Denmark, Department of Pediatrics, Pediatric Research Unit, Kolding Hospital, Kolding DK 6000, Denmark.
    • ,
  • Eric D. Bateman, MD

      Affiliations

    • Division of Pulmonology, Department of Medicine, University of Cape Town, Cape Town, South Africa
    • ,
  • Jean Bousquet, MD

      Affiliations

    • Hôpital Arnaud de Villeneuve, Montpellier, France
    • ,
  • William W. Busse, MD

      Affiliations

    • Department of Medicine, University of Wisconsin–Madison Medical School, Madison, Wis
    • ,
  • Sally Yoxall, MSc

      Affiliations

    • GlaxoSmithKline, Greenford, Middlesex, United Kingdom
    • ,
  • Tim J. Clark, MD

      Affiliations

    • National Heart and Lung Institute, Imperial College, London, United Kingdom
    • ,
  • Gaining Optimal Asthma controL Steering Committee and Investigators

Received 15 February 2007 ,Revised 5 July 2007 ,Accepted 12 July 2007.

  • Image Result

    Influence of smoking status on the proportion of patients achieving WC asthma at the end of phase II (A) and exacerbation rates (B; all strata). Comparison for exacerbation rates was made by using the

    Influence of smoking status on the proportion of patients achieving WC asthma at the end of phase II (A) and exacerbation rates (B; all strata). Comparison for exacerbation rates was made by using the Poisson model, adjusting for baseline, stratum, sex, age, smoking status, and smoking by treatment interaction.

  • Image Result
    Number of individual criteria passed by patients with NWC asthma (all strata).

    Number of individual criteria passed by patients with NWC asthma (all strata).

 The funding for the original Gaining Optimal Asthma controL study (GSK study no. CCC3456788) from which these data were derived was from GlaxoSmithKline R&D.

 Disclosure of potential conflict of interest: S. E. Pedersen has consulting arrangements with GlaxoSmithKline, Nycomed, and Merck and has received grant support from GlaxoSmithKline, Nycomed, and AstraZeneca. E. D. Bateman has consulting arrangements with GlaxoSmithKline, AstraZeneca, Boehringer Ingelheim, Altana, Kyowa Hakko, Hoffman La Roche, Almirall, and Merck and is on the speakers' bureau for GlaxoSmithKline, AstraZeneca, Boehringer Ingelheim, and Altana. J. Bousquet has consulting arrangements with and has received grant support from GlaxoSmithKline. W. W. Busse has consulting arrangements with Genentech/Novartis, Isis, GlaxoSmithKline, Altana, Wyeth, Pfizer, Dynavax, and Centocor; has received grant support from Novartis, Wyeth, Dynavax, and Centocor; and is on the speakers' bureau for GlaxoSmithKline, Novartis, Merck, and AstraZeneca. S. Yoxall is employed by GlaxoSmithKline. T. J. Clark has consulting arrangements with GlaxoSmithKline.

PII: S0091-6749(07)01387-5

doi: 10.1016/j.jaci.2007.07.016

The Journal of Allergy and Clinical Immunology
Volume 120, Issue 5 , Pages 1036-1042 , November 2007

Article Tools

* Image Usage & Resolution